- Home
- ACTG vs ZBIO Comparison
ACTG vs ZBIO Comparison
Compare ACTG & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- ZBIO
- Stock Information
- Founded
- ACTG 1993
- ZBIO 2019
- Country
- ACTG United States
- ZBIO United States
- Employees
- ACTG N/A
- ZBIO N/A
- Industry
- ACTG Multi-Sector Companies
- ZBIO
- Sector
- ACTG Miscellaneous
- ZBIO
- Exchange
- ACTG Nasdaq
- ZBIO NYSE
- Market Cap
- ACTG 387.5M
- ZBIO 389.2M
- IPO Year
- ACTG 1996
- ZBIO 2024
- Fundamental
- Price
- ACTG $3.20
- ZBIO $7.90
- Analyst Decision
- ACTG
- ZBIO Strong Buy
- Analyst Count
- ACTG 0
- ZBIO 7
- Target Price
- ACTG N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- ACTG 305.1K
- ZBIO 189.9K
- Earning Date
- ACTG 03-13-2025
- ZBIO 05-16-2025
- Dividend Yield
- ACTG N/A
- ZBIO N/A
- EPS Growth
- ACTG N/A
- ZBIO N/A
- EPS
- ACTG N/A
- ZBIO N/A
- Revenue
- ACTG $122,312,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- ACTG $86.80
- ZBIO N/A
- Revenue Next Year
- ACTG N/A
- ZBIO N/A
- P/E Ratio
- ACTG N/A
- ZBIO N/A
- Revenue Growth
- ACTG N/A
- ZBIO N/A
- 52 Week Low
- ACTG $3.19
- ZBIO $5.83
- 52 Week High
- ACTG $5.74
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ACTG 20.28
- ZBIO N/A
- Support Level
- ACTG $3.28
- ZBIO N/A
- Resistance Level
- ACTG $3.38
- ZBIO N/A
- Average True Range (ATR)
- ACTG 0.15
- ZBIO 0.00
- MACD
- ACTG -0.03
- ZBIO 0.00
- Stochastic Oscillator
- ACTG 0.93
- ZBIO 0.00
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon. Acacia operates its businesses based on three key principles of people, process, and performance and has built a management team with demonstrated expertise in research, transactions and execution, and operations and management.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.